BiotechTube

CDZ173

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Common Variable Immunodeficiency (CVID), APDS / PASLI

Conditions

Common Variable Immunodeficiency (CVID), APDS / PASLI

Trial Timeline

Aug 24, 2015 → Aug 16, 2021

NCT ID
NCT02435173

About CDZ173

CDZ173 is a phase 2/3 stage product being developed by Novartis for Common Variable Immunodeficiency (CVID), APDS / PASLI. The current trial status is completed. This product is registered under clinical trial identifier NCT02435173. Target conditions include Common Variable Immunodeficiency (CVID), APDS / PASLI.

What happened to similar drugs?

5 of 17 similar drugs in Common Variable Immunodeficiency (CVID), APDS / PASLI were approved

Approved (5) Terminated (3) Active (10)
✅Pseudoephedrine/ParacetamolJohnson & JohnsonApproved
✅Dextromethorphan + PlaceboNovartisApproved
✅VivaglobinCSLApproved
✅Acetylsalicylic acid (Aspirin, BAYE4465) + Paracetamol + PlaceboBayerApproved
✅Aspirin (Acetylsalicylic acid, BAYE4465) + PlaceboBayerApproved
🔄Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mgNovartisPhase 3
🔄XylometazolineNovartisPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02435173Phase 2/3Completed

Competing Products

20 competing products in Common Variable Immunodeficiency (CVID), APDS / PASLI

See all competitors
ProductCompanyStageHype Score
Nasal Glucagon + OxymetazolineEli LillyPhase 1
29
New Formulation Phenylephrine HCl + Marketed Phenylephrine HCl + PlaceboJohnson & JohnsonPhase 2
27
Pseudoephedrine/ParacetamolJohnson & JohnsonApproved
43
Zostavax®MerckPre-clinical
18
Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mgNovartisPhase 3
40
Dextromethorphan + PlaceboNovartisApproved
35
XylometazolineNovartisPhase 3
40
N-acetylcysteine + PlaceboNovartisPhase 2
35
Advil Congestion Relief + Advil Allergy and Congestion Relief + ParacetamolPfizerPhase 3
32
pseudoephedrine hydrochloride 30 mg tablets + Placebo tabletsPfizerPhase 3
40
gammaglobulinCSLPre-clinical
26
Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)CSLPhase 3
40
VivaglobinCSLApproved
43
Acetylsalicylic acid (Aspirin, BAYE4465) + Paracetamol + PlaceboBayerApproved
40
Aspirin (Acetylsalicylic acid, BAYE4465) + PlaceboBayerApproved
40
Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain + Acetylsalicylic Acid (Aspirin, BAYE4465) + Lidocain + PlaceboBayerPhase 3
37
Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine + Acetylsalicylic Acid (Aspirin, BAYE4465) + Pseudoephedrine + PlaceboBayerPhase 3
37
Acetylsalicylic Acid (Aspirin, BAYE4465) + Pseudoephedrine + PlaceboBayerPhase 3
37
Acetylcysteine + Paracetamol + PhenylephrineSandoz GroupPhase 3
29
A-101Aclaris TherapeuticsPhase 3
30